Intermediateclinical correlationsArticle
Myasthenia Gravis: The Story of a Blocked Signal
Learning objectives
- Describe normal acetylcholine signaling at the neuromuscular junction.
- Explain how autoantibodies reduce the safety factor of neuromuscular transmission.
- Relate receptor loss to fatigable weakness and ocular predominance.
- Describe the thymus connection in myasthenia gravis.
Act one: the signal crosses the junction
Every voluntary movement begins when a motor neuron fires an action potential that releases acetylcholine (ACh) into the synaptic cleft of the neuromuscular junction. ACh binds nicotinic receptors on the muscle’s end plate, opening ion channels that generate an end-plate potential. Normally this potential overshoots the firing threshold by a wide margin — the ‘safety factor’ — so transmission is essentially fail-proof.
Act two: the intruder arrives
In most myasthenia gravis, the immune system produces IgG autoantibodies against the ACh receptor itself. They bind receptors and trigger complement-mediated destruction, flattening the junctional folds that normally amplify the signal. A smaller group of patients has antibodies against MuSK, a protein that clusters receptors — same story, different target. Fewer functional receptors means a shrinking safety factor: the signal still arrives, but the end-plate potential barely reaches threshold.
Act three: weakness that tires
Here is the signature of the disease. With repeated nerve firing, the amount of ACh released per impulse declines slightly — a normal phenomenon called rundown. Healthy junctions have receptors to spare; myasthenic junctions do not. So the first contractions succeed while later ones fail, producing weakness that worsens with activity and recovers with rest. The eye muscles fail first because their motor units are tiny and fire constantly to hold gaze — they have the smallest safety margins in the body.
Fatigable weakness is the mechanical consequence of a reduced safety factor: each successive impulse releases slightly less acetylcholine, and a junction with too few receptors cannot sustain transmission.
The thymus subplot
The thymus, where T cells learn self-tolerance, is abnormal in most patients — hyperplastic in younger patients, sometimes harboring a thymoma. Thymic tissue can express ACh-receptor-like proteins, offering a plausible origin for the misdirected immune response. The thymus connection is why myasthenia gravis is studied as a model autoimmune disease: the target, the antibodies, and the broken tolerance are all unusually clear.
This content is educational only and is not medical advice.
Key points
- Myasthenia gravis is an antibody-mediated attack on neuromuscular junction proteins, most often the ACh receptor.
- Complement-mediated loss of junctional folds reduces the safety factor of transmission.
- Fatigable weakness reflects normal ACh rundown acting on a receptor-depleted junction.
- Ocular muscles fail first because their small motor units have minimal safety margins.
- Thymic abnormalities link the disease to broken immune self-tolerance.
Common misconceptions
✓ Truth: The muscle fibers themselves are healthy. The defect is in transmission — the signal fails to cross the neuromuscular junction, which is why strength returns with rest.
✓ Truth: Its defining feature is fluctuation: weakness worsens with repeated use and improves with rest, separating it from most other causes of weakness.
✓ Truth: Ocular symptoms — drooping eyelids and double vision — are the commonest first signs, but the disease frequently generalizes to bulbar, limb, and respiratory muscles.
Frequently asked questions
What is the ‘safety factor’ of the neuromuscular junction?
It is the excess of end-plate potential over the threshold needed to fire the muscle fiber. A large safety factor means transmission succeeds even when conditions are imperfect. Myasthenia gravis shrinks this margin by removing functional receptors, so normal variations in acetylcholine release become enough to cause transmission failure.
Why do symptoms fluctuate during the day?
Because transmission depends on the balance between acetylcholine release and available receptors. After rest, stored acetylcholine is plentiful and contractions succeed; with sustained activity, release per impulse declines and the depleted receptor population can no longer compensate — weakness appears, then recovers after rest.
What is the difference between AChR and MuSK myasthenia?
Both are autoimmune, but the antibody target differs. Anti-AChR antibodies destroy the receptors themselves via complement. Anti-MuSK antibodies disrupt the clustering of receptors at the end plate by blocking a signaling protein. The downstream effect — failed transmission — is the same, though the patterns of muscle involvement can differ.
Why is the thymus involved?
The thymus trains T cells to ignore the body’s own proteins. In myasthenia gravis it is often hyperplastic or contains a thymoma, and thymic tissue can express proteins resembling the acetylcholine receptor — a plausible site where self-tolerance to the junction breaks down.